Chemotherapy of gastric cancer

Anti-Cancer Drugs

Volumn 7, Issue 2, 1996, Pages 137-149

  Schipper, D L ^a   Wagener, D J T ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

adjuvant; chemotherapy; combination; gastric cancer; preoperative; single agent

Indexed keywords

ANTINEOPLASTIC AGENT; BISANTRENE; CARBOPLATIN; CARMOFUR; CARMUSTINE; CHLORAMBUCIL; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; HYDROXYUREA; IRINOTECAN; METHOTREXATE; MITOGUAZONE; MITOMYCIN C; SEMUSTINE; THIOTEPA; TRIAZINATE;

ADVANCED CANCER; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL TRIAL; DIARRHEA; DRUG RESPONSE; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; METASTASIS; MUCOSA INFLAMMATION; NEPHROTOXICITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENT CANCER; REVIEW; STOMACH ADENOCARCINOMA; SURVIVAL; VOMITING;

EID: 0030000717     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199602000-00001     Document Type: Review

References (165)

1. Dupont JB, Lee JR, Burton GR, et al. Adenocarcinoma of the stomach: review of 1497 cases. Cancer 1987; 41: 941-53.
2. Cocconi G. Chemotherapy of advanced gastric carcinoma: to be completely rewritten? Ann Oncol 1194; 5: 8-11.
3. Wils JA. Perspectives in chemotherapy of advanced gastric cancer. Anti-Cancer Drugs 1991; 2: 133-7.
4. Findlay M, Cunningham D. Chemotherapy of carcinoma of the stomach. Cancer Treat Rev 1993; 19: 29-44.
5. Kelsen D. The use of chemotherapy in the treatment of advanced gastric and pancreatic cancer. Semin Oncol 1994; 21 (Suppl 7): 58-66.
6. Sulkes A, Cavalli F, van Oosterom A, et al. Taxotere is active in advanced gastric carcinoma: results of a phase II clinical trial. Eur J Cancer 1993; 23A: S101 (Abstr 539) (Suppl 6).
7. Kambe M. Wakui A, Nakao I, et al. A late phase II study of irinotecan (CPT-11) in patients with advanced gastric cancer. Proc Am Soc Clin Oncol 1993; 12: 198 (Abstr 584).
8. Comis R. Integration of chemotherapy into combined modality treatment of solid tumors. Cancer Treat Rev 1974; 1: 22-33.
9. Cocconi G, DeLisi V, Di Blasio B. Randomized comparison of 5-FU alone or combined with mitomycin and cytarabine (MCF) in the treatment of advanced gastric cancer. Cancer Treat Rev 1982; 66: 1263-6.
10. Fraile RJ, Baker LH, Buroker TR, et al. Pharmacokinetics of 5-fluorouracil administered orally, by rapid intravenous and by slow infusion. Cancer Res 1980; 40: 2223-8.
11. Lokich J, Ahlgren J, Gullo J, et al. A prospective randomised comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma. A mid-Atlantic Oncology Program Study. J Clin Oncol 1989; 7: 425-32.
12. Moynihan T, Hansen R, Anderson T, et al. Continuous 5-fluorouracil infusion in advanced gastric carcinoma. Am J Clin Oncol 1988; 11: 461-4.
13. Preusser P, Achterrath W, Wilke H, et al. Chemotherapy of gastric cancer. Cancer Treat Rev 1988; 15: 257-77.
14. Einzig A, Kelsen DP, Cheng E. Phase II trial of carboplatin in patients with adenocarcinomas of the upper gastrointestinal tract. Cancer Treat Rep 1985; 69: 1453-4.
15. Gueritte-Voegelein F. Relationships between the structure of taxol analogues and their antimitotic activity. J Med Chem 1991; 83: 288-91.
16. MacDonald JS, Wooley PV, Smythe T, et al. 5-Fluorouracil, adriamycin and mitomycin-C (FAM) combination chemotherapy in the treatment of advanced gastric cancer. Cancer 1979; 44: 42-7.
17. Cullinan SA, Moertel CG, Fleming TR, et al. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma: fluorouracil versus fluorouracil and doxorubicin versus fluorouracil, doxorubicin and mitomycin. J Am Med Ass 1985; 253: 2061-7.
18. Cullinan SA, Moertel CG, Wieand HS, et al. Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer. J Clin Oncol 1994; 12: 412-6.
19. Beretta G, Arnoldi E, Beretta GD, et al. A randomized study of fluorouracil versus FAM polychemotherapy in gastric carcinoma. In: Proc EORTC Symp in Advances in gastrointestinal tract cancer research and treatment, Strasbourg, 1989; Abstr 48.
20. Klein HO. Long-term results with FAMTX (5-fluorouracil, adriamycin, methotrexate) in advanced gastric cancer. Anticancer Res 1989; 9: 1025-6.
21. Wils J, Klein HO, Wagener DJTh, et al. Sequential high-dose methotrexate and fluorouracil combined with doxorubicin - a step ahead in the treatment of advanced gastric cancer: a trial of the European Organisation for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol 1991; 9: 827-31.
22. Evans RM, Laskin JD, Hakala MT. Effect of excess folates and deoxyinosine on the activity and site of action of 5-fluorouracil. Cancer Res 1981; 41: 3288-95.
23. Machover D, Goldschmidt E, Chollet P, et al. Treatment of advanced colorectal and gastric adenocarcinomas with 5-FU and high-dose folonic acid. J Clin Oncol 1986; 4: 685-90.
24. Preusser P, Wilke H, Achterrath W, et al. Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer. J Clin Oncol 1989; 7: 1310-7.
25. Kelsen D, Atiq OT, Saltz L, et al. FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer. J Clin Oncol 1992. 10: 541-8.
26. Stahl M, Wilke H, Preusser P, et al. Etoposide leucovorin and 5-fluorouracil (ELF) in advanced gastric carcinoma - final results of a phase II study in elderly patients or patients with cardial risk. Onkologie 1991; 14: 314-8.
27. Findlay M, Cunningham D, Norman A, et al. A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol 1994; 5: 609-16.
28. Delfino C, Caccia C, Fein L, et al. for the Argentine Cooperative Group. Cisplatin, epirubicin and 5-fluorouracil in patients with advanced gastric cancer. Eur J Cancer 1991; S81 (Suppl 2).
29. Zaniboni A, Labianca R, Martignoni G, et al. ECF is an active feasible regimen for advanced gastric cancer. A Giscad confirmatory study. Ann Oncol 1994; 5 (Suppl 8): 79 (Abstr P395).
30. Murad AM, Santiago FF, Petroianu A, et al. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993; 72: 37-41.
31. Pyrhönen S, Kuitunen T, Kouri M. A randomized, phase III trial comparing fluorouracil, epidoxorubicin and methotrexate (FEMTX) with best supportive care in non resectable gastric cancer. Ann Oncol 1992; 3 (Suppl 5): 12 (Abstr).
32. Glimelius B, Hoffman K, Haglund U, et al. Initial or delayed chemotherapy with best supportive care in advanced gastric cancer. Ann Oncol 1994; 5: 189-90.
33. Hermans J, Bonenkamp JJ, Boon MC, et al. Adjuvant therapy after curative resection for gastric cancer: metaanalysis of randomized trials. J Clin Oncol 1993; 11: 1441-7.
34. Pignon JP, Ducreux M, Rougier P, et al. Meta-analysis of adjuvant chemotherapy in gastric cancer: a critical reappraisal. Meta-analyses need time, collaboration and funding. J Clin Oncol 1994; 12: 877-80.
35. Douglass HO Jr. Adjuvant therapy of gastric cancer: have we made any progress? Ann Oncol 1994; 5 (Suppl 3): 69-72.
36. Wils J, Meyer H-J, Wilke H. Current status and future directions in the treatment of localized gastric cancer. Ann Oncol 1994; 5 (Suppl 3): 69-72.
37. Bleiberg H, Gerard B, Deguiral P. Adjuvant therapy in resectable gastric cancer Br J Cancer 1992; 66: 987-91.
38. Agboola O. Adjuvant treatment in gastric cancer. Cancer Treat Rev 1994; 20: 217-40.
39. Wilke H, Preusser P, Fink U, et al. Preoperative chemotherapy in locally advanced and nonresectable gastric cancer: a phase II study with etoposide, doxorubicin, and cisplatin. J Clin Oncol 1989; 7: 1318-26.
40. Kang YK, Choi DW, Kim CM, et al. The effect of neoadjuvant chemotherapy on the surgical outcome of locally advanced gastric adenocarcinoma: interim report of a randomized controlled trial. Proc Am Soc Clin Oncol 1992; 11: 173 (Abstr 505).
41. Bruckner HW, Lokich JJ, Stablein DM. Studies of Baker's antifol, methotrexate, and razozane in advanced gastric cancer: a gastrointestinal tumor study group report. Cancer Treat Rep 1982; 66: 1713-7.
42. Moore G, Bross I, Ausman R, et al. Effects of chlorambucil (NSC 3088) in 374 patients with advanced cancer. Cancer Chemother Rep 1968; 52: 661-6.
43. Pannettiere F, Jones S, Oishi N, et al. Bisantrene hydrochloride in gastric adenocarcinoma: a Southwest Oncology Group Study. Med Pediatr Oncol 1986; 14: 78-80.
44. Ravry M, Omura G, Hill G, et al. Phase II evaluation of mitoguazone in cancers of the esophagus, stomach and pancreas: a Southeastern Cancer Study Group trial. Cancer Treat Rep 1986; 70: 533-4.
45. Sessa C, Aamdal S, Wolff I, et al. Gemcitabine in patients with advanced malignant melanoma or gastric cancer: phase II studies of the EORTC Early Clinical Trials Group. Ann Oncol 1994; 5: 471-2.
46. Christman K, Kelsen D, Saltz L, et al. Phase II trial of gemcitabine in patients with advanced gastric cancer. Cancer 1994; 73: 5-7.
47. Bitran J, Desser R, Kozloff M, et al. Treatment of metastatic pancreatic and gastric adenocarcinomas with 5- fluorouracil, adriamycin, and mitomycin-C (FAM). Cancer Treat Rep 1979; 63: 2049-51.
48. The Gastrointestinal Tumor Study Group. A comparative clinical assessment of combination chemotherapy in the management of advanced gastric carcinoma. Cancer 1982; 49: 1362-6.
49. MacDonald JS, Schein PS, Woolley BV, et al. 5-Fluorouracil, doxorubicin, and mitomycin (FAM) combination chemotherapy for advanced gastric cancer. Ann Intern Med 1980; 93: 533-6.
50. Faedi M, Amadori M, Gentilini P, et al. Chemotherapy of advanced gastric cancer: a study of 43 consecutive cases treated with fluorouracil, adriamycin and mitomycin C (FAM). Chemiotherapia 1986; 5: 240-3.
51. Ridolfi R, Casadei-Giunchi D, Cortesi C, et al. A retrospective study of FAM regimen in 38 patients with advanced gastric cancer. Tumori 1984; 70: 375-9
52. Fornasiero A, Cartei G, Daniele O, et al. FAM2 regimen in disseminated gastric cancer. Tumori 1984; 70: 77-80.
53. Gill PG, Jones AM, Abbott R. Chemotherapy of advanced gastric cancer. Austr NZ J Surg 1983; 53: 237-40.
54. Figoli F, Galligioni E, Crivellari D, et al. Evaluation of 2 consecutive regimens in advanced gastric cancer. Cancer Invest 1991; 9: 257-62.
55. Cocconi G, Bella M, Zironi S, et al. Fluorouracil, doxorubicin, and mitomycin combination versus PELF chemotherapy in advanced gastric cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research. J Clin Oncol 1994; 12: 2687-93.
56. Douglass HO Jr, Lavin PT, Goudsmid A, et al. An Eastern Cooperative Oncology Group evaluation of combinations of methyl-CCNU, mitomycin C, Adriamycin, and 5-fluorouracil in advanced measurable gastric cancer (EST (2277). J Clin Oncol 1984; 2: 1372-81.
57. Beretta G, Fraschini P, Labianca R, et al. The value of FAM polychemotherapy in advanced gastric carcinoma. Proc Am Soc Clin Oncol 1982; 5: 103 (Abstr C-400).
58. The Southwest Oncology Group. 5-Fluorouracil, adriamycin, and mitomycin-C ± vincristine (FAM vs. V-FAM) compared to chlorozotocin, M-AMSA and dihydroxyanthracenedione with unimpressive differences. Proc Am Soc Clin Oncol 1983; 2: 122.
59. Cummingham D, Soukop M, McArdle C, et al. Advanced gastric cancer: experience in Scotland using 5-fluorouracil, adriamycin, and mitomycin-C. Br J Surg 1984; 71: 673-6.
60. Haim N, Cohen Y, Honigman J, et al. Treatment of advanced gastric carcinoma with 5-fluorouracil, adriamycin, and mitomycin-C (FAM). Cancer Chemother Pharmacol 1982; 8: 277-80.
61. Pannettiere FJ, Haas Ch, McDonald B, et al. Drug combinations in the treatment of gastric adenocarcinoma. J Clin Oncol 1984; 2: 420-4.
62. The Gastrointestinal Tumor Study Group. Randomized study of combination chemotherapy in unresectable gastric cancer. Cancer 1984; 53: 13-7.
63. Biran H, Sulkes A. A possible dose-response relationship in 'FAM' chemotherapy for advanced gastric cancer. Proc Am Soc Clin Oncol 1984; 132 (Abstr C-515).
64. De Lisi V, Bella M, Soldani M, et al. The FAM combination versus the combination of Cisplatin, Adriamycin and Mitomycin (PAM) in advanced gastric cancer. A phase III study of the Italian oncology group for clinical research (GOIRC). Proc ECCO 1987; 4: 37 (Abstr 141).
65. Haas C, Oishi N, McDonald B, et al. Southwest Oncology Group phase II-III gastric cancer study: 5-Fluorouracil, Adriamycin, and Mitomycin-C + Vincristine (FAM vs. V-FAM) compared to Chlorozotocin (CZT), M-AMSA, and Dihydroxyanthracenedione (DHAD) with unimpressive differences. Proc Am Soc Clin Oncol 1983; 2: 122 (Abstr C-478).
66. Beretta G, Fraschini P, Labianca R, et al. Weekly 5- fluorouracil (F) versus combination chemotherapy for advanced gastrointestinal carcinomas. A prospective study program. Proc Am Soc Clin Oncol 1986; 5: 94 (Abstr C-367).
67. Icli F, Karaoguz H, Dicol D, et al. Comparison of EAP and FAM combination chemotherapies in advanced gastric cancer. Proc Am Soc Clin Oncol 1993; 12: 207 (Abstr 619).
68. The Gastrointestinal Tumor Study Group. Triazinate and platinum efficacy in combination with 5-fluorouracil and doxorubicin: results of a three arm randomized trial in metastatic gastric cancer. J Natl Cancer Inst 1988; 80: 1011-5.
69. Epelbaum R, Haim M, Stein M, et al. Treatment of advanced gastric cancer with DDP (cisplatin), adriamycin, and 5-fluorouracil (DAF). Oncology 1987; 44: 201-6.
70. Cazap EL, Gisselbrecht C, Smith FP, et al. Phase II trials of 5-FU, doxorubicin and cisplatin in advanced, measurable adenocarcinoma of the lung and stomach. Cancer Treat Rep 1986; 70: 781-3.
71. Wagener DJ, Yap SH, Wobbes T, et al. Phase II trial of 5- fluorouracil, adriamycin and cisplatin (FAP) in advanced gastric cancer. Cancer Chemother Pharmacol 1985; 15: 86-7.
72. Moertel CG, Rubin J, O'Connell MJ, et al. A phase II study of combined 5-fluorouracil, doxorubicin and cisplatin in the treatment of advanced upper gastrointestinal adenocarcinomas. J Clin Oncol 1986; 4: 1053-7.
73. Rougier P, Droz JP, Theodore C, et al. Phase II trial of combined 5-fluorouracil plus doxorubicin plus cisplatin (FAP regimen) in advanced gastric carcinoma. Cancer Treat Rep 1987; 71: 1301-2.
74. Woolley P, Smith F, Estevez R, et al. A phase II trial of 5- FU, Adriamycin and Cisplatin (FAP) in advanced gastric cancer. Proc Am Soc Clin Oncol 1981; 455: (Abstr C-481).
75. Figoli F, Calligioni E, Crivellari D, et al. Cisplatin (DDP) in combination with Adriamycin (A), and Fluorouracil (F) (DAF) in advanced gastric cancer - a phase II study. Proc Am Soc Clin Oncol 1986; 95: (Abstr C-369).
76. Levi JA, Fox RM, Tattersall MH, et al. Analysis of a prospectively randomized comparison of doxorubicin versus 5-fluorouracil, doxorubicin, and BCNU in advanced gastric cancer: implications for future studies. J Clin Oncol 1986; 4: 1348-55.
77. Lopez M, Perno CF, Di-Lauro L, et al. 5-Fluorouracil, adriamycin, and BCNU (FAB) combination chemotherapy for advanced gastric cancer. Cancer Chemother Pharmacol 1984; 12: 194-7.
78. Schnitzler G, Queisser W, Heim ME, et al. Phase III study of 5-FU and carmustine versus 5-FU, carmustine and doxorubicin in advanced gastric cancer. Cancer Treat Rep 1986; 70: 477-9.
79. Levi JA, Dalley DN, Aroney RS. Improved combination chemotherapy in advanced gastric cancer. Br Med J 1979; 2: 1471-3.
80. Lopez M, Di Lauro L, Papaldo P, et al. Treatment of advanced measurable gastric carcinoma with 5-Fluorouracil, Adriamycin, and BCNU. Oncology 1986; 43: 288-91.
81. The Gastrointestinal Tumor Study Group. Phase II-III chemotherapy studies in advanced gastric cancer. Cancer Treat Rep 1979; 63: 1871-6.
82. Lacave A, Wils J, Bleiberg H, et al. An EORTC gastrointestinal group phase III evaluation of combinations of Methyl-CCNU, 5-Fluorouracil, and Adriamycin in advanced gastric cancer. J Clin Oncol 1987; 5: 1387-93.
83. Buroker T, Kim P, Grappe C, et al. 5-FU infusion with mitomycin-C versus 5-FU infusion with methyl-CCNU in the treatment of advanced upper gastrointestinal cancer. Cancer 1979; 44: 1215-21.
84. Moertel CG, Lavin PT. Phase II-III chemotherapy studies in advanced gastric cancer. Eastern Cooperative Oncology Group. Cancer Treat Rep 1979; 63: 1863-9.
85. Baker LH, Talley RW, Matter R, et al. A Southwest Oncology Group Study. Phase III comparison of the treatment of advanced gastrointestinal cancer with bolus weekly 5-FU VS. methyl-CCNU plus bolus weekly 5-FU. Cancer 1976; 38: 1-7.
86. Moertel CG, Mittleman JA, Bakemeier RF, et al. Sequential and combination chemotherapy of advanced gastric cancer. Cancer 1976; 38: 678-82.
87. Wils J, Bleiberg H, Dalesio O, et al. An EORTC gastrointestinal group evaluation of the combination of sequential methotrexate and 5-fluorouracil, combined with adriamycin in advanced measurable gastric cancer. J Clin Oncol 1986; 4: 1799-803.
88. Ajani JA, Goudeau P, Levin B, et al. Phase II study of adriamycin with sequential methotrexate and 5-fluorouracil (AMF) in gastric carcinoma. Cancer Chemother Pharmacol 1989; 24: 41-4.
89. Herrmann R, Fritze D, Queisser W, et al. Chemotherapie des Magenkarzinoms. Dtsch Med Wschr 1984; 109: 1704.
90. Scherdin G, Garbrecht M, Muellerleile U, et al. Polychemotherapy with methotrexate in medium doses range, 5-fluorouracil and adriamycin in advanced gastric carcinoma. J Cancer Res Clin Oncol 1936; 111: 85 (Suppl ) (Abstr Sto 14).
91. Muro H, Romero Acuna K, Castagnari A, et al. Sequential methotrexate, 5-fluorouracil (high-dose) and doxorubicin for advanced gastric cancer. Cancer Treat Rep 1986; 70: 1333-4.
92. Weh HJ, Platz D, Garbrecht M, et al. Ergebnisse eines modifizierten FAMethehemotherapieprotokolls beim metastasierten magenkarzinom. Dtsch Med Wschr 1989; 114: 1391-6.
93. Massuti B, Cervantes A, Aranda E, et al. A phase III multicenter randomized study in advanced gastric cancer (GC): fluorouracil + leucovorin + epirubicin + cisplatin (FLEP) versus fluorouracil + adriamycin + methotrexate + Leucovorin (FAMTX). In: Proc 2nd Int Conf on Biology, Prevention and Treatment of Gastrointestinal Malignancies, Koln, 1995; 50.
94. Vanhoefer U, Wilke H, Wils J, et al. Preliminary analysis of a randomized phase III trial of FAMTX versus ELF versus Cisplatin/FU in advanced gastric cancer (GC). A trial of the EORTC Gastrointestinal Tract Cancer Cooperative Group and the AIO (Arbeitsgemeinschaft Internistische Onkologie). In: Proc 2nd Int Conf on Biology, Prevention and Treatment of Gastrointestinal Malignancies, Koln, 1995; 71.
95. Gebbia V, Valenza R, Testa A, et al. Etoposide, doxorubicin (adriamycin) and cisplatin regimen in advanced gastric adenocarcinoma: experience with a lower dose schedule. J Cancer Res Clin Oncol 1994; 120: 550-2.
96. Rath U, Flechtner H, Selbach J, et al. Etoposide, adriamycin, and cisplatin (EAP) combination chemotherapy for advanced gastric cancer. A phase II trial by the 'Chemotherapiegruppe Gastrointestinaler Tumoren (CGT)'. Onkologie 1990; 13: 194-7.
97. Wilke H, Preusser P, Fink U, et al. New developments in the treatment of gastric carcinoma. Semin Oncol 1990; 17 (Suppl 2): 61-70.
98. Lerner A, Gonin R, Steele GD Jr, et al. Etoposide, doxorubicin, and cisplatin chemotherapy for advanced gastric adenocarcinoma: Results of a phase II trial. J Clin Oncol 1992; 4: 536-40.
99. Sparano JA, Schwartz EL, Salva KM, et al. Phase II trial of etoposide, doxorubicin (adriamycin), and cisplatin (EAP regimen) in advanced gastric cancer. Am J Clin Oncol 1990; 13: 374-8.
100. Katz A, Gansi RC, Simon SD, et al. Phase II trial of etoposide (V), adriamycin (A) and cisplatinum (P) in patients with advanced gastric cancer. Am J Clin Oncol 1991; 14: 357-8.
101. Haim N, Tsalik M, Robinson E. Treatment of advanced gastric carcinoma with VP-16, adriamycin and cisplatin (EAP). Eur J Cancer 1993; 29A: S102 (Abstr 549) (Suppl 6).
102. Roth AD, Herrmann R, Thuerlimann B, et al. Cisplatin, adriamycin and VP-16 (PAV) in advanced gastric carcinoma (AGC): the Sakk experience. Ann Oncol 1994; 5 (Suppl 8): 85 (Abstr 426).
103. Jovanovic DM, Muzikravic Lj, Antonic M, et al. Evaluation of the combination of chemotherapy with etoposide, adriamycin and cisplatin (EAP) in advanced or recurrent gastric cancer. Ann Oncol 1994; 5 (Suppl 8): 85 (Abstr 427).
104. Taal BG, Teller FGM, Ten Bokkel Huinink WW, et al. Etoposide leucovorin, 5-fluorouracil (ELF) combination chemotherapy for advanced gastric cancer: experience with two treatment schedules incorporating intravenous or oral etoposide. Ann Oncol 1994; 5: 90-2.
105. Di Bartolomeo M, Bajetta E, de Braud F, et al. Phase II study of the etoposide, leucovorin and fluorouracil combination for patients with advanced gastric cancer unsuitable for aggressive chemotherapy. Oncology 1995; 52: 41-4.
106. Suspiro A, Oliveira J, Lage P, et al. Low activity of etoposide + folinic acid + 5fluorouracil (ELF) in advanced gastric cancer. Ann Oncol 1994; 5 (Suppl 8): 88 (Abstr 441).
107. De Braud F, Bajetta E, Di Bartolomeo M, et al. Etoposide, leucovorin and fluorouracil (ELF) regimen in the treatment of advanced gastric cancer (AGC). An Italian Trials in Medical Oncology (I.T.M.O.) study. Proc Am Soc Clin Oncol 1993; 12: 210 (Abstr 632).
108. McDonald A, Harding M, McNulty L, et al. A pilot study of cisplatin based combination chemotherapy in gastric cancer. Clin Oncol R Coll Radiol 1993; 5: 284-5.
109. Taal BG, Ten Bokkel Huinink WW, Simonetti G, et al. A phase II trial of sequential MTX and 5-FU alternated with 4′-epidoxorubicin and cisplatin in advanced gastric cancer. Cancer Invest 1990; 8: 501-4.
110. Roelofs EJ, Wagener DJTh, Conroy T, et al. Phase II study of sequential high-dose methotrexate (MTX) and 5-fluorouracil (F) alternated with epirubicin (E) and cisplatin (P) (FEMTX-P) in advanced gastric cancer. Ann Oncol 1993; 4: 426-8.
111. Wils JA, Coombes RC, Bliss JM, et al. Phase I-II study of sequential high dose methotrexate and 5-fluorouracil combined with epirubicin (FEMTX) at different dose levels in advanced gastric cancer. GI Cancer 1995; 1: 55-9.
112. Ychou M, Fedkovic Y, Saint Aubert B, et al. A phase II study with 5-FU, leucovorin and cisplatin in metastatic gastric cancer. Eur J Cancer 1993; 29A: S106 (Abstr 573) (Suppl 6).
113. Im YH, Kang YK, Kim CM, et al. A phase II trial of low dose leucovorin, 5-fluorouracil and cisplatin (LV-FP) combination chemotherapy in patients with advanced gastric adenocarcinoma. Proc Am Soc Clin Oncol 1994; 13: 207 (Abstr 616).
114. Wilke H, Vanhoefer U, Fink U, et al. Weekly high-dose FU/folinic acid (HD-FU/FA) and cisplatin (C): a safe and active combination for advanced gastric cancer (GC). In: Proc 2nd Int Conf on Biology, Prevention and Treatment of Gastrointestinal Malignancies, Koln, 1995; 72.
115. Wilke H, Vanhoefer U, Fink U, et al. Weekly high-dose FU/folinic acid (HD-FU/FA) plus biweekly cisplatin (C) = (Group A) or HD-FU/FA plus alternating C/epidoxorubicin (E) = (Group B) for gastric cancer (GC). Ann Oncol 1994; 5; (Suppl 8): 80 (Abstr P397).
116. Cervantes A, Villar-Grimalt A, Abad A, et al. 5-Fluorouracil, folinic acid, epidoxorubicin and cisplatin (FLEP) combination chemotherapy in advanced measurable gastric cancer. A phase II trial of the Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD). Ann Oncol 1993; 4: 753-7.
117. Wilke H, Vanhoefer U, Fink U, et al. Pilot study with a weekly 24h-infusion of 5-FU/folinic acid (HD-FU/FA) plus weekly alternating cisplatin (C) and epidoxorubicin (E) for advanced gastric cancer (GC). In: Proc 2nd Int Conf on Biology, Prevention and Treatment of Gastrointestinal Malignancies, Koln, 1995; 53.
118. Crivellari D, Buonadonna A, Sorio R, et al. Feasibility and activity of a 3-day PELF like regimen in advanced gastric cancer, preliminary data. In: Proc 2nd Int Conf on Biology, Prevention and Treatment of Gastrointestinal Malignancies, Koln, 1995; 59.
119. Ducreux M, Yakendji K, Rougier Ph, et al. First line combined chemotherapy with 5-fluorouracil (5-FU), folinic acid, epirubicin and cisplatin (FLEP) in advanced gastric cancer: the Gustave Roussy Institute experience. Ann Oncol 1994; 5 (Suppl 8): 79 (Abstr P394).
120. Kornek G, Schulz F, Depisch D, et al. A phase I-II study of epirubicin, 5-fluorouracil, and leucovorin in advanced adenocarcinoma of the stomach. Cancer 1993; 71: 2177-80.
121. Louvet C, De Gramont A, Beerblock K, et al. Hydroxyurea, leucovorin, 5FU and cisplatin (HLFP regimen) in advanced gastric cancer. In: Proc 2nd Int Conf on Biology, Prevention and Treatment of Gastrointestinal Malignancies, Koln, 1995.
122. Kyoto Research Group for Chemotherapy of Gastric Cancer (KRGCGC). A randomized, comparative study of combination chemotherapies in advanced gastric cancer: 5-fluorouracil and cisplatin (FP) versus 5-fluorouracil, cisplatin, and 4′-epidoxorubicin (FPEPIR). Anticancer Res 1992; 12: 1983-8.
123. Lacave AJ, Baron FJ, Anton LM, et al. Combination chemotherapy with cisplatin and 5-fluorouracil 5-day infusion in the therapy of advanced gastric cancer: a phase II trial. Ann Oncol 1991; 2: 751-4.
124. Ohtsu A, Yoshida S, Saito D, et al. An early phase II study of 5-fluorouracil combined with cisplatin as a second line chemotherapy against metastatic gastric cancer. Jpn J Clin Oncol 1991; 21: 120-4.
125. Rougier P, Ducreux M, Mahjoubi M, et al. Efficacy of combined 5-fluorouracil and cisplatinum in advanced gastric carcinomas. A phase II trial with prognostic factor analysis. Eur J Cancer 1994; 30A: 1263-9.
126. Weitzen R, Ghodsizadeh A, Brenner H, et al. Gastric carcinoma: continuous infusion 5-fluorouracil plus cisplatinum: dose intensification study. Eur J Cancer 1993; 29A: S104 (Abstr 560) (Suppl 6).
127. Schmitz SH, Voliotis DL, Schimke J, et al. Continuous 5- fluorouracil and leucovorin as a second-line therapy for advanced gastric carcinoma. Oncology 1994; 51: 502-6.
128. Cascinu S, Fedeli A, Luzi Fedeli S, et al. Treatment of elderly advanced gastric cancer patients with 5-fluorouracil and leucovorin combination. J Chemother 1992; 4: 185-8.
129. Arbuck SG, Douglass HO, Trave F, et al. A phase II trial of 5-fluorouracil and high-dose intravenous leucovorin in gastric carcinoma. J Clin Oncol 1987; 5: 1150-6.
130. Vanhoefer U, Wilke H, Weh H, et al. Weekly high-dose 5-FU/Folic acid is active in chemotherapeutically pre- treated gastric cancer. Ann Oncol 1994; 5 (Suppl 8): 80 (Abstr P398).
131. Longmire WP Jr, Kuzma JW, Dixon WJ. The use of triethylenethiophosphoramide as an adjuvant to the surgical treatment gastric carcinoma. Ann Surg 1968; 167: 293-312.
132. Serlin O, Wolkoff JS, Amadeo JM, et al. The use of 5- fluorodeoxiuridine (FUDR) as an adjuvant to the surgical management of carcinoma of the stomach. Cancer 1969; 24: 223-8.
133. Sautner T, Hofbauer F, Depisch D, et al. Adjuvant intraperitoneal cisplatin chemotherapy does not improve long-term survival after surgery for advanced gastric cancer. J Clin Oncol 1994; 12: 970-4.
134. Grau JJ, Estape J, Alcobendas F, et al. Positive results of adjuvant mitomycin C in resected gastric cancer: a randomised trial on 134 patients. Eur J Cancer 1993; 29A: 340-2.
135. Estape J, Grau JJ, Lcobendas F, et al. Mitomycin C as an adjuvant treatment to resected gastric cancer. A 10-year follow-up. Ann Surg 1991; 213: 219-21.
136. Nakajima T, Fukami A, Ohashi I, et al. Long-term follow up study of gastric cancer patients treated with surgery and adjuvant chemotherapy with mitomycin C. Int J Clin Pharmacol 1978; 16: 209-16.
137. Hagiwara A, Takahashi T, Kojima O, et al. Prophylaxis with carbon-absorbed mitomycin against peritoneal recurrence of gastric cancer. Lancet 1992; 339: 629-31.
138. Chou FF, Sheen-Chen SM, Liu PP, et al. Adjuvant chemotherapy for resectable gastric cancer: a preliminary report. J Surg Oncol 1994; 57: 239-42.
139. Douglas HO, Stablein DM, Bruckner HM, et al. Controlled trial of adjuvant chemotherapy following curative resection for gastric cancer The Gastrointestinal Tumor Study Group. Cancer 1982; 49: 1116-22.
140. Schlag P. Adjuvant chemotherapy in gastric cancer. World J Surg 1987; 11: 473-7.
141. Blake JR, Hardcastle JD, Wilson RG. Gastric cancer: a controlled trial of adjuvant chemotherapy following gastrectomy. J Clin Oncol 1981; 7: 13-21.
142. Allum WH, Hallissey MT, Kelly KA. Adjuvant chemotherapy in operable gastric cancer. 5 year follow- up of first British Stomach Cancer Group Trial. Lancet 1989; 1: 571-4.
143. Allum WH, Hallissey MT, Ward LC, et al. A controlled prospective, randomised trial of adjuvant chemotherapy or radiotherapy in resectable gastric cancer: interim report. British Stomach Cancer Group. Br J Cancer 1989; 60: 739-44.
144. The Italian Gastrointestinal Tumor Study Group. Adjuvant treatments following curative resection for gastric cancer. Br J Surg 1988; 75: 1100-4.
145. The Gastrointestinal Tumor Study Group. Controlled trial of adjuvant chemotherapy following curative resection for gastric cancer. Cancer 1982; 49: 1116-22.
146. Higgins GA, Amadeo JH, Smith DE, et al. Efficacy of prolonged intermittent therapy with combined 5-FU and methyl-CCNU following resection for gastric carcinoma. A Veterans Administration Surgical Oncology Group Report. Cancer 1983; 52: 1105-12.
147. Engstrom PF, Lavin PT, Douglass HO Jr, et al. Postoperative adjuvant 5-fluorouracil plus methyl-CCNU therapy for gastric cancer patients. Eastern Cooperative Oncology Group Study (EST 3275). Cancer 1985; 55: 1868-73.
148. Nakajima T, Takahashi T, Takagi K, et al. Comparison of 5-fluorouracil with ftorafur in adjuvant chemotherapies with combined inductive and maintenance therapies for gastric cancer. J Clin Oncol 1984; 2: 1366-71.
149. Hallissey MT, Dunn JA, Ward LC, et al. The second British Stomach Cancer group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer: five-year follow up. Lancet 1994; 343: 1309-12.
150. Krook JE, O'Connell MJ, Wieand HS, et al. A prospective, randomized evaluation of intensive course 5-fluorouracil plus doxorubicin as surgical adjuvant chemotherapy for resected gastric cancer Cancer 1991; 67: 2454-8.
151. Maehara Y, Moriguchi S, Sakaguchi Y, et al. Adjuvant chemotherapy enhances long-term survival of patients with advanced gastric cancer following curative resection. J Surg Oncol 1990; 45: 169-72.
152. Coombes RC, Schein PS, Chilvers CE, et al. A randomized trial comparing adjuvant fluorouracil doxorubicin, and mitomycin with no treatment in operable gastric cancer. International Collaborative Cancer Group. J Clin Oncol 1990; 8: 1362-9.
153. Macdonald JS, Gagliano R, Fleming T, et al. A phase II trial of FAM (5-fluorouracil, adriamycin, mitomycin-C) chemotherapy vs control as adjuvant treatment for resected gastric cancer (A Southwest Oncology Group Trial - SWOG 7804). Proc Am Soc Clin Oncol 1992; 11: 168.
154. Hugier M, Destroyes JP, Baschet C, et al. Gastric carcinoma treated by chemotherapy after resection. Am J Surg 1980; 139: 1105-12.
155. Nakajima T, Fukami A, Tagaki K, et al. Adjuvant chemotherapy with mitomycin C and with a multi-drug combination of mitomycin C, 5-fluorouracil and cytosine arabinoside after curative resection of gastric cancer. Jpn J Clin Oncol 1980; 10: 187-94.
156. Jakesz R, Dittrich C, Funovics J, et al. The effect of adjuvant chemotherapy in gastric carcinoma is dependent on tumor histology: 5-year results of a prospective randomized trial. Recent Res Cancer Res 1988; 110: 44-51.
157. Rosen HR, Scheithauer W, Jakesz R, et al. Epirubicin, Etoposide and Cisplatin in the treatment of locally advanced, nonresectable gastric carcinoma - results of a multicentric pilot study. GI Cancer 1995; 1: 49-53.
158. Plukker JTh, Mulder NH, Sleijfer DTh, et al. Chemotherapy and surgery for locally advanced cancer of the cardia and fundus: phase II study with methotrexate and 5-fluorouracil. Br J Surg 1991; 78: 955-8.
159. Schuhmacher CH, Fink U, Boettcher K, et al. Neoadjuvant chemotherapy for locally advanced gastric cancer: a phase II study with etoposide, adriamycin and cisplatin (EAP). Ann Oncol 1994; 5 (Suppl 8): 76 (Abstr O380).
160. Ajani JA, Ota DM, Jessup JM, et al. Resectable gastric carcinoma. An evaluation of preoperative and postoperative chemotherapy. Cancer 1991; 68: 1501-6.
161. Leichman L, Silberman H, Leichman CG, et al. Preoperative systemic chemotherapy followed by adjuvant postoperative intraperitoneal therapy for gastric cancer: a University of Southern California pilot program. J Clin Oncol 1992; 10: 1933-42.
162. Ajani JA, Mayer RJ, Ota DM, et al. Preoperative and postoperative combination chemotherapy for potentially resectable gastric carcinoma. J Nat Cancer Inst 1993; 85: 1839-44.
163. Rougier Ph, Lasser Ph, Ducreux M, et al. Preoperative chemotherapy of locally advanced gastric cancer. Ann Oncol 1994; 5 (Suppl 3): 59-68.
164. Fink U, Schuhmacher CH, Bottcher K, et al. Neoadjuvant chemotherapy (EAP) with r-metHuG-CSF (Filgastrim) for patients with locally advanced gastric cancer. Eur J Cancer 1993; 29A: S55 (Abstr 272) (Suppl 6).
165. Kelsen D, Karpeh M, Schwartz G, et al. Neoadjuvant and postoperative chemotherapy for high-risk gastric cancer. Proc Am Soc Clin Oncol 1994; 13: 195 (Abstr 566).